Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPAGNELLI, CarolineGUIMARAES, ThaisSUKIENNIK, TeresaLIMA, Paulo Roberto PassosSALLES, Mauro JoseBREDA, Giovanni LuisQUEIROZ-TELLES, FlavioMAGRI, Marcello Mihailenko ChavesMENDES, Ana VerenaCAMARGO, Luis Fernando AranhaMORALES, HugoDIAS, Viviane Maria de Carvalho HesselROSSI, FlaviaCOLOMBO, Arnaldo Lopes2023-06-212023-06-212023JOURNAL OF FUNGI, v.9, n.4, article ID 468, 11p, 2023https://observatorio.fm.usp.br/handle/OPI/54165Candidemia remains a major public health challenge due to its high mortality rates, especially in developing countries. Monitoring epidemiological trends may provide insights for better clinical outcomes. This study aimed to describe trends in the epidemiology, therapeutic practices, and mortality in candidemia through a retrospective comparative analysis between two surveillance cohorts of all candidemic adults at eleven tertiary hospitals in Brazil, from 2010-2011 (Period I) versus 2017-2018 (Period II). A total of 616 cases were diagnosed, with 247 being from Period II. These patients were more likely to have three or more coexisting comorbidities [72 (29.1%) vs. 60 (16.3%), p < 0.001], had a prior history of in-hospital admissions more often [102 (40.3%) vs. 79 (21.4%), p = 0.001], and presented with candidemia earlier after admission, within 15 days (0-328) vs. 19 (0-188), p = 0.01. Echinocandins were more frequently prescribed [102 (41.3%) vs. 50 (13.6%), p = 0.001], but time to antifungal initiation [2 days (0-14) vs. 2 (0-13), p = 0.369] and CVC removal within 48 h [90/185 (48.6%) vs. 148/319 (46.4%), p = 0.644] remained unchanged. Additionally, many patients went untreated in both periods I and II [87 (23.6%) vs. 43 (17.4%), p = 0.07], respectively. Unfortunately, no improvements in mortality rates at 14 days [123 (33.6%) vs. 93 (37.7%), p = 0.343] or at 30 days [188 (51.4%) vs. 120 (48.6%), p = 0.511] were observed. In conclusion, mortality rates remain exceedingly high despite therapeutic advances, probably associated with an increase in patients' complexity and suboptimal therapeutic interventions. Management strategies should be tailored to suit epidemiological changes, expedite diagnosis to reduce the number of untreated eligible patients and guarantee early antifungal initiation and source control.engopenAccesscandidemiainvasive candidiasismortalityprognosisantifungal therapyescmid-asterisk guidelinecritically-ill patientsinvasive candidiasisantifungal therapymortalityepidemiologymanagementimpactpredictorsdiagnosisarticleCopyright MDPI10.3390/jof9040468MicrobiologyMycology2309-608X